The Amino Acid Asn136 in HIV-1 Reverse Transcriptase (RT) Maintains Efficient Association of Both RT Subunits and Enables the Rational Design of Novel RT Inhibitors
Open Access
- 1 July 2005
- journal article
- research article
- Published by Elsevier in Molecular Pharmacology
- Vol. 68 (1) , 49-60
- https://doi.org/10.1124/mol.105.012435
Abstract
The highly conserved Asn136 is in close proximity to the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI)-specific lipophilic pocket of human immunodeficiency virus type 1 (HIV-1) RT. Site-directed mutagenesis has revealed that the catalytic activity of HIV-1 RT mutated at position Asn136 is heavily compromised. Only 0.07 to 2.1% of wild-type activity is retained, depending on the nature of the amino acid change at position 136. The detrimental effect of the mutations at position 136 occurred when the mutated amino acid was present in the p51 subunit but not in the p66 subunit of the p51/p66 RT heterodimer. All mutant enzymes could be inhibited by second-generation NNRTIs such as efavirenz. They were also markedly more sensitive to the inactivating (denaturating) effect of urea than wild-type RT, and the degree of increased urea sensitivity was highly correlated with the degree of (lower) catalytic activity of the mutant enzymes. Replacing wild-type Asn136 in HIV-1 RT with other amino acids resulted in notably increased amounts of free p51 and p66 monomers. Our findings identify a structural/functional role for Asn136 in stabilization of the RT p66/p51 dimer and provide hints for the rational design of novel NNRTIs or drugs targeting either Asn136 in the β7–β8 loop of p51 or its anchoring point on p66 (the peptide backbone of His96) so as to interfere with the RT dimerization process and/or with the structural support that the p51 subunit provides to the p66 subunit and which is essential for the catalytic enzyme activity.Keywords
This publication has 33 references indexed in Scilit:
- High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of MutationsJournal of Virology, 2005
- TSAO Compounds: The Comprehensive Story of a Unique Family of HIV- 1 Specific Inhibitors of Reverse TranscriptaseCurrent Topics in Medicinal Chemistry, 2004
- Chimeric Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Reverse Transcriptases: Role of the Subunits in Resistance/Sensitivity to Non-Nucleoside Reverse Transcriptase InhibitorsMolecular Pharmacology, 2002
- Strategies in the design of antiviral drugsNature Reviews Drug Discovery, 2002
- DiscussionBiochemical Pharmacology, 1999
- Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroupsAntiviral Research, 1995
- Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptaseAntimicrobial Agents and Chemotherapy, 1994
- Sensitivity of (138 Glu → Lys) Mutated Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase (RT) to HIV-1-Specific RT InhibitorsBiochemical and Biophysical Research Communications, 1994
- Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.Proceedings of the National Academy of Sciences, 1993
- Quantitative analysis of protein far UV circular dichroism spectra by neural networksProtein Engineering, Design and Selection, 1992